San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin ...

In September of last year, the FDA said it had begun exploring the potential health effects of various metals that have been ...

Will 2025 be better? After another tough year, the answer to that question will shape the prospects of innumerable drug ...

Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds ...

After being acquired by clinical-stage ADC company Oqory, Vincerx ended 2024 with a workforce reduction and C-suite clear-out ...

Investor David Lazar has come to the rescue of cash-strapped Cyclacel Pharmaceuticals, pumping $3 million into the biotech as ...

Last December, the FDA published its final guidance on predetermined change control plans, or PCCPs, with recommendations to ...

Now, China-based CARsgen has shared pivotal results from the latter portion of a phase 1/2 study evaluating the therapy for ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in ...

Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of ...

Neumora Therapeutics’ big bet on a new era of neuroscience has delivered an age-old result. The first of three late-stage ...